DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) yesterday and set a price target of ...

In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Aurora Pharmaceutical logo "Our sales team is the backbone of our customer relationships, and this expansion reflects both our business growth and our dedication to providing best-in-class service to ...

A scientist at the Moderna pharmaceutical company in Massachusetts said, “mRNA allows us to turn you into a little manufacturing powerhouse facility.” He went on to say, “Another benefit is ...

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...

$126,056 from the pharmaceutical industry and $109,065 from hospitals and nursing homes over the same period. Massachusetts is home to Moderna, the manufacturer of an mRNA SARS-CoV-2 vaccine ...